GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.

A rangy man stepped to the microphone at Sahuarita’s town hall and started raging about “gingers” — red-haired people. “We got to choke every ginger in town,” said the man, Mark Brown. “We can’t have ...

In retrospect, it makes sense that Daniel Hollander’s case brought tensions between Tucson police and the Pima County Attorney’s Office out into the open. Hollander put himself in a position to commit ...